Abstract
Mycobacterium tuberculosis (Mtb), due to its unusual organization crosses different immune barriers and causes tuberculosis. The advent of multidrug resistance tuberculosis (MDR-TB) has attained alarming situation. Hence, computational drug design has been performed in this work to find potent molecules for this purpose.
Isoniazid is a widely used frontline drug against tuberculosis. But reports justified the inactivity of isoniazid on acetylation by Arylamine N-acetyltransferase (NAT). 35 countries were highlighted to have isoniazid resistance from survey in 1998. Hence, Mtb NAT has been selected as the target in the present case and hundred compounds were screened in order to find potent NAT inhibitor to raise the efficacy of isoniazid.
Molecular docking with Biosolveit LeadIT and Autodock 4.2 simulation was performed. The result showed 7- methylpicene-1, 2-diol to have -26.77 and -8.26 kcal/mol score in LeadIT and Autodock 4.2. The work validated 7- methylpicene-1, 2-diol to be a potent NAT inhibitor to supplement isoniazid.
Keywords: Anti-tubercular drug, Arylamine N-acetyltransferase, isoniazid, MDR-TB, NAT, 7-methylpicene-1, 2-diol.
Combinatorial Chemistry & High Throughput Screening
Title:High Throughput Screening of 7-Methylpicene-1,2-Diol as Arylamine N-Acetyltransferase (NAT) Inhibitor to Establish a Isoniazid Supplement in Anti-Tubercular Therapy
Volume: 16 Issue: 9
Author(s): Abhishek Chowdhury, Paulomi Paul and Manabendra Dutta Choudhury
Affiliation:
Keywords: Anti-tubercular drug, Arylamine N-acetyltransferase, isoniazid, MDR-TB, NAT, 7-methylpicene-1, 2-diol.
Abstract: Mycobacterium tuberculosis (Mtb), due to its unusual organization crosses different immune barriers and causes tuberculosis. The advent of multidrug resistance tuberculosis (MDR-TB) has attained alarming situation. Hence, computational drug design has been performed in this work to find potent molecules for this purpose.
Isoniazid is a widely used frontline drug against tuberculosis. But reports justified the inactivity of isoniazid on acetylation by Arylamine N-acetyltransferase (NAT). 35 countries were highlighted to have isoniazid resistance from survey in 1998. Hence, Mtb NAT has been selected as the target in the present case and hundred compounds were screened in order to find potent NAT inhibitor to raise the efficacy of isoniazid.
Molecular docking with Biosolveit LeadIT and Autodock 4.2 simulation was performed. The result showed 7- methylpicene-1, 2-diol to have -26.77 and -8.26 kcal/mol score in LeadIT and Autodock 4.2. The work validated 7- methylpicene-1, 2-diol to be a potent NAT inhibitor to supplement isoniazid.
Export Options
About this article
Cite this article as:
Chowdhury Abhishek, Paul Paulomi and Choudhury Dutta Manabendra, High Throughput Screening of 7-Methylpicene-1,2-Diol as Arylamine N-Acetyltransferase (NAT) Inhibitor to Establish a Isoniazid Supplement in Anti-Tubercular Therapy, Combinatorial Chemistry & High Throughput Screening 2013; 16 (9) . https://dx.doi.org/10.2174/13862073113169990004
DOI https://dx.doi.org/10.2174/13862073113169990004 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
subject Index To Volume 3
Current Drug Targets Developments on Drug Delivery Systems for the Treatment of Mycobacterial Infections
Current Topics in Medicinal Chemistry γ δ T Cell Modulation in Anticancer Treatment
Current Cancer Drug Targets Therapeutic Benefits of <i>Piper nigrum</i>: A Review
Current Bioactive Compounds Mechanisms of Corticosteroid Resistance in Severe Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Current Pharmaceutical Design Internet Resources for Drug Discovery and Design
Current Topics in Medicinal Chemistry UPLC-ESI-Q-TOF/MS Based Metabolic Profiling of Protosappanin B in Rat Plasma, Bile, Feces, Urine and Intestinal Bacteria Samples
Current Drug Metabolism Probiotics/Prebiotics in Viral Respiratory Infections: Implication for Emerging Pathogens
Recent Patents on Biotechnology Virtual Screening Against M. tuberculosis 7,8-Diaminopelargonic Acid Synthase (MtbBioA) and In Silico Toxicity Evaluation of Top Hits
Current Enzyme Inhibition An Integrated Drug Development Approach Applying Topological Descriptors
Current Computer-Aided Drug Design An Overview on Pyranocoumarins: Synthesis and Biological Activities
Current Organic Chemistry Novel Pharmacologic Approaches to the Management of Sepsis: Targeting the Host Inflammatory Response
Recent Patents on Inflammation & Allergy Drug Discovery Patent Selections
Recent Patents on Biotechnology Withdrawal Notice: Evaluation of Clinical Profile, Diagnostic Tests, And Prognosis of Crypto-coccal Meningitis in HIV Infected Patients in Western India
Infectious Disorders - Drug Targets Therapeutic Proteins and Nanotechnology: Immune Response and Stealth Bioengineered Constructs
Current Drug Metabolism Ferroquine: A New Weapon in the Fight Against Malaria
Current Medicinal Chemistry - Anti-Infective Agents TNF-α in Tuberculosis: A Cytokine with a Split Personality
Inflammation & Allergy - Drug Targets (Discontinued) A Review on Pharmacological Properties of Coumarins
Mini-Reviews in Medicinal Chemistry Ureas: Applications in Drug Design
Current Medicinal Chemistry Natural Products as Leads for Tuberculosis Drug Development
Current Topics in Medicinal Chemistry